---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-091959"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:10:45.818819+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics

## Summary
- Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.
- Commercial agreements now cover ~60% of US outpatient dialysis centers; four of top five dialysis providers.
- Cash and short-term investments $46.0M as of Sep 30, 2024; sufficient for at least 12 months.
- Operating expenses $14.1M, up 34% YoY due to selling, marketing, G&A for launch.
- Clinical study protocol for TPN indication amendment to be submitted to FDA by mid-November; study start H1 2025.

## SEC filing metadata
- accession: 0001213900-24-091959
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390024091959/0001213900-24-091959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390024091959/ea0219021-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-091959
- JSON: https://secwatch.observer/filing/0001213900-24-091959.json
- Plain text: https://secwatch.observer/filing/0001213900-24-091959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.